Neuland Laboratories Limited — PPTs, 12-05-2026: Investor Presentation

Neuland Labs delivered a strong show in FY26! Revenue jumped 37.1% YoY to Rs. 2053.1 Cr, with Profit After Tax (PAT) soaring 40% to Rs. 363.1 Cr. EBITDA margin expanded to a robust 29.4%. Growth was largely fueled by its Contract Manufacturing Solutions (CMS) business, driven by commercial molecules, and key molecules like Ezetimibe in the Prime segment.

Looking ahead, Neuland is strategically investing in Peptide Manufacturing and a new state-of-the-art R&D Centre, positioning itself to capture the rapidly growing global peptide API market, projected to hit $14Bn by 2030. The company filed 2 new Drug Master Files (DMFs) in FY26 and made significant capital expenditure of Rs. 397 Cr for future expansion.

Management highlighted strong business visibility for the short to medium term and is building foundations for long-term sustainable growth. With FY26 EPS at Rs. 283 and Return on Capital Employed (ROCE) at 26.1%, Neuland remains financially sound with a net cash position.